Email this article Efficiency of cyclosporin A therapy in patients with myelodysplastic syndrome
- Authors: Kokhno AV1, Parovichnikova EN1, Mikhailova EA1, Ustinova EN1, Kaplanskaya IB1, Dvirnyk VN1, Olshanskaya Y.V1, Domracheva EV1, Savchenko VG1
-
Affiliations:
- Hematology Research Center, Russian Academy of Medical Sciences, Moscow
- Issue: Vol 82, No 8 (2010)
- Pages: 48-53
- Section: Editorial
- Submitted: 09.04.2020
- Published: 15.08.2010
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30643
- ID: 30643
Cite item
Full Text
Abstract
Subjects and methods. The efficacy of CsA was evaluated in 52 patients (30 men and 22 women aged 16 to 74 years) with MDS. Thirty-two patients were given CsA as first-line therapy; 20 patients took the agent after prior therapy. CsA was used in a daily oral dose of 5 mg/kg. Its efficacy was evaluated following 3, 6, and 12 months. Actuarial survival was determined by the Kaplan-Meier method.
Results. The efficacy of CsA used as first- and second-line therapy was 56 and 55%, respectively; complete remissions were achieved in 19 and 20% of cases. Baseline refractory anemia (RA) transformed to RA with excess blasts (RAEB) in 31% of cases; baseline RAEB did to acute myeloid leukemia in 34%. Overall survival was significantly associated with bone marrow (BM) blast cell percentage ( < 5% or > 5%; p = 0.0009), BM cellularity (hypoplasia and focal hypoplasia of hematopoiesis or BM hyperplasia; p = 0.03), focal polyclonal lymphoid infiltration in the BM (p = 0.01) and karyotype anomalies (low, moderate, and high risks; p = 0.001).
Conclusion. CsA is the drug of choice in treating patients with MDS, including RA, RA with ringed sideroblasts, refractory cytopenia with multilineage dysplasia, with hypoplasia of hematopoiesis, with nodular polyclonal lymphoid infiltration in the BM, a normal karyotype or changes corresponding to a low or moderate IPSS risk.
About the authors
A V Kokhno
Hematology Research Center, Russian Academy of Medical Sciences, Moscow
Email: alina@blood.ru
Hematology Research Center, Russian Academy of Medical Sciences, Moscow
E N Parovichnikova
Hematology Research Center, Russian Academy of Medical Sciences, MoscowHematology Research Center, Russian Academy of Medical Sciences, Moscow
E A Mikhailova
Hematology Research Center, Russian Academy of Medical Sciences, MoscowHematology Research Center, Russian Academy of Medical Sciences, Moscow
E N Ustinova
Hematology Research Center, Russian Academy of Medical Sciences, MoscowHematology Research Center, Russian Academy of Medical Sciences, Moscow
I B Kaplanskaya
Hematology Research Center, Russian Academy of Medical Sciences, MoscowHematology Research Center, Russian Academy of Medical Sciences, Moscow
V N Dvirnyk
Hematology Research Center, Russian Academy of Medical Sciences, MoscowHematology Research Center, Russian Academy of Medical Sciences, Moscow
Yu V Olshanskaya
Hematology Research Center, Russian Academy of Medical Sciences, MoscowHematology Research Center, Russian Academy of Medical Sciences, Moscow
E V Domracheva
Hematology Research Center, Russian Academy of Medical Sciences, MoscowHematology Research Center, Russian Academy of Medical Sciences, Moscow
V G Savchenko
Hematology Research Center, Russian Academy of Medical Sciences, MoscowHematology Research Center, Russian Academy of Medical Sciences, Moscow
References
- Савченко В. Г., Паровичникова Е. Н., Михайлова Е. А. и др. Миелодиспластический синдром: некоторые вопросы патогенеза и лечения. Тер. арх. 1996; 68 (7): 34-37.
- Bennett J., Catovsky D., Daniel M. et al. Proposals for the classification of the myelodysplastic syndrome. Br. J. Haematol. 1982; 51: 189-199.
- Valent P., Horny H-P., Bennett J. M. et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leukemia Res. 2007; 31: 727-736.
- Tuzuner N., Cox C., Rowe J. M., Watrous D. et al. Hypocellular myelodysplastic syndrome (MDS): new proposals. Br. J. Haematol. 1995; 91; 612-617.
- Козинец Г. И., Высоцкий В. В., Оприщенко С. А. Кровь и старение. Медицинская литература, 2009, 15-31.
- Huang T., Ko B., Hsu C. et al. Comparison of hypoplasic myelodysplastic syndrome with normo-/hypercellular MDS by IPSS, cytogenetic and genetic studies. Haematologica 2007; 92 (suppl. 1): abstr. 0228.
- Baumann I., Scheid C., Koref M. et al. Autologous lymphocytes inhibit hemopoesis in long-term culture in patients with myelodysplastic syndromes. Exp. Hematol. 2002; 30: 1405-1411.
- Molldrem J., Jiang Y., Stetler-Stevenson M. et al. Hematological response of patients with myelodysplastic syndromes to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br. J. Haematol. 1998; 102; 1314-1322.
- Kitagawa M., Saito I., Kuwata T. et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (INF)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997; 11: 2049-2054.
- Melenhorst J., Eniafe R., Follmann D. et al. Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome. Br. J. Haematol. 2002; 119; 97-105.
- Greenberg P. L. ed. Myelodysplastic syndromes. Clinical end biological advances. New York; 2006. 147-169.
- Killick S., Mufti G., Cavenagh J. et al. A pilot study of antithymocyte globin (ATG) in the treatment of patients with " low-risk" myelodysplasia. Br. J. Haematol. 2003; 120; 679-684.
- Steensma D., Dispenzieri A., Moore S. et al. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 2003; 101: 2156-2158.
- Козинец Г. И., Дульцина С. М., Дягилева О. А., Потапова С. Г. Цитохимическая характеристика гемопоэтических клеток здоровых людей: Метод. рекомендации. M.; 1980.
- Vardimir J. W., Harris N. L., Brunning R. D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
Supplementary files
